How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks
AbbVie Inc. (ABBV), a global biopharmaceutical company, trades at a market cap of $386.3 billion, categorizing it among mega-cap stocks. The company's key therapeutic areas encompass immunology, neuroscience, oncology, and aesthetics. Since April, ABBV has been trading beneath its 200-day moving average while maintaining an above-50-day average.
In July, the company announced a strong Q2 2026, with revenue growing 10.2% year-over-year and adjusted EPS increasing 22.9%. However, investors are concerned about the near-term impact of ABBV's $10.9 billion Apogee Therapeutics acquisition, which is anticipated to dilute 2026 adjusted EPS by $0.14, partially offset by $0.10 of stronger-than-expected performance.
Wall Street's sentiment on ABBV is moderately optimistic, with an overall consensus of "Strong Buy" from 31 analysts and a mean price target of $276.37, indicating an 8.2% potential upside from the current price.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
